title: Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH.
abstract: Since hematology is a highly specialized field, an individual physician may not have much direct treatment experience with a given disease. Therefore, the Japanese Society of Hematology (JSH) has discussed establishing a registry of hematologic disorders, in order to contribute to improving the quality of treatments and clinical outcomes in this field. As a first step, the Timely and Appropriate Registration System for GLIVEC Therapy (TARGET), a registration system for chronic myeloid leukemia (CML) patients treated with imatinib, was established in October 2003. We present the preliminary results of the first 4 years' experience with this system. CML patients treated with imatinib in Japan were registered through the website and the patient's clinical course, including parameters and events like imatinib dose, blood counts, adverse events, and efficacy were recorded in months 1, 3, 6, 9, and 12 and then every 6 months thereafter. By September 2007, 862 patients from 176 hospitals were registered. Follow-up period was 0-54 months, and 127 patients were followed-up for more than 36 months. Based on these cumulative data, present imatinib treatment trends were analyzed and safety and efficacy were compared with international trial data.
authors.affiliation: Department of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. makizaki@saitama-med.ac.jp.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kizaki
authors.affiliation: Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Okamoto
authors.affiliation: First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan.
authors.forename: Tetsuzo
authors.initials: T
authors.lastname: Tauchi
authors.affiliation: Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
authors.forename: Hideo
authors.initials: H
authors.lastname: Tanaka
authors.affiliation: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
authors.affiliation: Division of Hematology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Koiti
authors.initials: K
authors.lastname: Inokuchi
authors.affiliation: Hematology Division, Department of Medicine, Hyogo Cancer Center, Hyogo, Japan.
authors.forename: Tohru
authors.initials: T
authors.lastname: Murayama
authors.affiliation: Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Saburi
authors.affiliation: Clinical Hematology and Clinical Diagnosis, Graduate School of Medicine, Osaka City University, Osaka, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
authors.affiliation: Department of Hematology, Osaka Red Cross Hospital, Osaka, Japan.
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Tsudo
authors.affiliation: Department of Hematology, NTT Japan Kyushu Hospital, Kumamoto, Japan.
authors.forename: Taizo
authors.initials: T
authors.lastname: Shimomura
authors.affiliation: Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Isobe
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D005260:Female; D006405:Hematology; D006801:Humans; D000068877:Imatinib Mesylate; D020407:Internet; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012042:Registries; D012955:Societies, Medical; D014584:User-Computer Interface
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate